Paclitaxel encapsulated nanocells - EnGeneIC
Alternative Names: Erbitux®EDVsPacLatest Information Update: 15 Jan 2022
At a glance
- Originator EnGeneIC
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Immunostimulants; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Treatment-resistant) in Australia (IV, Infusion)
- 19 Aug 2009 Phase-I clinical trials in Solid tumours (late-stage disease, treatment resistant) in Australia (IV)